Literature DB >> 8325871

Carbohydrate-binding protein 35. II. Analysis of the interaction of the recombinant polypeptide with saccharides.

R N Knibbs1, N Agrwal, J L Wang, I J Goldstein.   

Abstract

The carbohydrate binding specificity of recombinant carbohydrate-binding protein 35 (rCBP35) has been investigated by quantitative precipitation using a series of glycoproteins and carbohydrate-protein conjugates and by inhibition of precipitation using well defined carbohydrate haptens. Synthetic glycoconjugates and glycoproteins containing terminal nonreducing galactosyl units in beta-linkage were capable of forming a precipitate with rCBP35. If the glycoprotein or glycoconjugate contained terminal Neu5Ac, or galactose in alpha-linkage, precipitate formation was not observed. We also found that murine laminin, which contains polylactosamine structures, reacted more strongly than did bovine fetuin. Using carbohydrate-bovine serum albumin (BSA) glycoconjugates, we found that the tetrasaccharide Gal beta 1, 4GlcNAc beta 1, 3Gal beta 1,4-GlcNAc-BSA reacted more strongly than the disaccharide Gal beta 1, 4GlcNAc-BSA conjugate, suggesting that the binding site accommodates carbohydrate ligands greater in size than a disaccharide. Equilibrium dialysis experiments using [3H]lactose showed that rCBP35 binds 1 mol (n = 0.84) of lactose/30,000 g atoms of protein, with an affinity constant of 2.07 x 10(4) M-1. The binding site on the polypeptide appears to contain four subsites that recognize the sequence Gal beta 1,4GlcNAc beta 1, Gal beta 1,X-. All disaccharides tested that contain a nonreducing beta-galactosyl unit behaved as inhibitors of precipitation at approximately the same concentration, suggesting that the reducing position of the tetrasaccharide does not play an important role in the specific binding to the fourth subsite. The reducing sugar may serve to hold the saccharide in a tunnel like binding pocket since methyl-beta-D-galactoside itself is an extremely poor inhibitor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8325871

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  Introduction to galectins.

Authors:  Hakon Leffler; Susanne Carlsson; Maria Hedlund; Yuning Qian; Francoise Poirier
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

2.  Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR.

Authors:  Hans Ippel; Michelle C Miller; Sabine Vértesy; Yi Zheng; F Javier Cañada; Dennis Suylen; Kimiko Umemoto; Cecilia Romanò; Tilman Hackeng; Guihua Tai; Hakon Leffler; Jürgen Kopitz; Sabine André; Dieter Kübler; Jesús Jiménez-Barbero; Stefan Oscarson; Hans-Joachim Gabius; Kevin H Mayo
Journal:  Glycobiology       Date:  2016-02-23       Impact factor: 4.313

3.  Characterization of LGALS3 (galectin-3) as a player in DNA damage response.

Authors:  Renato S Carvalho; Vanessa C Fernandes; Thales C Nepomuceno; Deivid C Rodrigues; Nicholas T Woods; Guilherme Suarez-Kurtz; Roger Chammas; Alvaro N Monteiro; Marcelo A Carvalho
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

4.  MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis.

Authors:  Yuichiro Suzuki; Mihoko Sutoh; Shingo Hatakeyama; Kazuyuki Mori; Hayato Yamamoto; Takuya Koie; Hisao Saitoh; Kanemitsu Yamaya; Tomihisa Funyu; Tomonori Habuchi; Yoichi Arai; Minoru Fukuda; Chikara Ohyama; Shigeru Tsuboi
Journal:  Int J Oncol       Date:  2012-03-23       Impact factor: 5.650

5.  Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  David J R Fulton; Xueyi Li; Zsuzsanna Bordan; Yusi Wang; Keyvan Mahboubi; R Daniel Rudic; Stephen Haigh; Feng Chen; Scott A Barman
Journal:  Antioxid Redox Signal       Date:  2019-03-29       Impact factor: 8.401

6.  Cell type-dependent alterations of binding of synthetic blood group antigen-related oligosaccharides in lung cancer.

Authors:  K Kayser; N V Bovin; T V Zemlyanukhina; S Donaldo-Jacinto; J Koopmann; H J Gabius
Journal:  Glycoconj J       Date:  1994-08       Impact factor: 2.916

Review 7.  Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update.

Authors:  Vanessa Leiria Campo; Marcelo Fiori Marchiori; Lílian Cataldi Rodrigues; Marcelo Dias-Baruffi
Journal:  Glycoconj J       Date:  2016-08-15       Impact factor: 2.916

8.  Sensing lectin-glycan interactions using lectin super-microarrays and glycans labeled with dye-doped silica nanoparticles.

Authors:  Xin Wang; Elena Matei; Lingquan Deng; Leonardus Koharudin; Angela M Gronenborn; Olof Ramström; Mingdi Yan
Journal:  Biosens Bioelectron       Date:  2013-03-21       Impact factor: 10.618

9.  Mutational tuning of galectin-3 specificity and biological function.

Authors:  Emma Salomonsson; Michael C Carlsson; Veronica Osla; Ruth Hendus-Altenburger; Barbro Kahl-Knutson; Christopher T Oberg; Anders Sundin; Rickard Nilsson; Eva Nordberg-Karlsson; Ulf J Nilsson; Anna Karlsson; James M Rini; Hakon Leffler
Journal:  J Biol Chem       Date:  2010-08-31       Impact factor: 5.157

10.  Identification and purification of a stress associated nuclear carbohydrate binding protein (M(r) 33,000) from rat liver by application of a new photoreactive carbohydrate probe.

Authors:  G Lauc; M Flögel; B Diehl-Seifert; H C Schröder; W E Müller
Journal:  Glycoconj J       Date:  1994-12       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.